Table 2.

Participant clinical courses

Participant ID	Diagnosis date time framea	SARS-CoV-2 therapies administered during the same hospitalization	Clinical course	Days to negative SARS-CoV-2 PCR from infusion	Days to discharge from infusion	Change in pulmonary radiographic findings
DVX201-001	9/2021–11/2021	remdesivir, dexamethasone	discharged home without complications	7	1	post-imaging not performed
DVX201-002	10/2021–12/2021	remdesivir, casirivimab and imdevimab (Regeneron), dexamethasone	started chemotherapy 5 days after infusion and discharged; readmitted for hypoxemic respiratory failure attributed to persistent COVID-19	53	13	improvement with subsequent worsening
DVX201-003	10/2021–12/2021	remdesivir, dexamethasone	discharged home without complications	7	1	improved
DVX201-004	11/2021–1/2022	remdesivir, dexamethasone	improved and discharged home off oxygen	N/Ab	3	post-imaging not performed
DVX201-006	1/2022–3/2022	remdesivir, dexamethasone	improved and discharged home off oxygen	0	2	post-imaging not performed
DVX201-007	1/2022–3/2022	remdesivir, dexamethasone	improved and discharged home off oxygen but with residual dyspnea with exertion	1	6	improved
DVX201-008	3/2022–5/2022	remdesivir, dexamethasone, nirmatrelvir-ritonavir	improved and discharged on 2 L oxygen; readmitted with persistent COVID-19	24	2	improvement with subsequent worsening
DVX201-009	3/2022–5/2022	remdesivir, dexamethasone	discharged home without complications	N/Ac	1	post-imaging not performed
DVX201-010	5/2022–7/2022	remdesivir	improved and discharged home	27	8	post-imaging not performed

^aGeneral time periods are provided to protect participant privacy.

^bLast positive test was on day 14 and indeterminate; participant refused subsequent testing.

^cOnly positive from bronchoalveolar lavage prior to enrollment and not retested. Nasopharyngeal swabs were negative.